Abstract:Abstract Among the prerequisites to be effective, immunotherapy must work in the presence of the host immunosuppression. Myeloid-derived suppressor cells (MDSCs) are one of the cellular mediators that have a role in limiting the induction of adaptive immune response and host responses to immunotherapy. MDSCs are an immature, heterogeneous cellular population, including hematopoietic precursors for granulocytes, macrophages, dendritic cells, and endothelial cells. They are infrequent in healthy hosts, but increase during tumor progression as a result of dysregulated myeloid cell expansion and differentiation. Tumor growth is frequently associated with an increased frequency of MDSCs that results in a loss in T-cell number and function through increased ROS and peroxynitrites production and arginase 1 (ARG1) and nitric oxide synthase 2 (NOS-2) upregulation. A better understanding of MDSCs expansion and the regulation of biodistribution and arrest would improve interventional strategies and cancer immunotherapy outcomes. Using five mammary tumor models, we have examined tumor-associated expansion of MDSCs and observed that this occurs in an organ-specific manner. Murine MDSCs can be subdivided into phenotypically and functionally distinct sub-populations according to Gr-1 expression levels; the CD11b+Gr-1 dim MDSCs with monocytic nuclei and strong T-cell suppressive activity, and CD11b+Gr-1bright having ring-shaped nuclei (polymorphonuclear cells) and a lower T-cell suppression profile. These cells can also be subset based on the expression of Ly-6C which is highly expressed on immature, bone marrow-derived cells and combined this Gr-1 expression Our studies revealed a significant increase in the Ly-6Cbright expression on the CD11b+Gr-1dim MDSCs in all organs studied in tumor-bearing mice as compared to non-tumor-bearing mice. In association with the increase in CD11b+Gr-1dimLy-6Cbright cells in the tumor non-parenchymal cells of 4T1 tumor bearing mice, increased transcripts levels of cytokines associated with MDSCs expansion (granulocyte-colony stimulating factor [G-CSF]) and MDSCs-associated immunosuppression (ARG-1, NOS-2, and cyclooxygenase 2 [COX-2]) while lower levels of these cytokines were observed in tumor NPCs from Cl66 tumor-bearing mice and non-tumor-bearing mice. In association with the increase in MDSCs and loss of T-cells in the 4T1 tumor-bearing mice there was a significant decrease in cytokine transcript levels that can enhance immune response (interferon gamma [IFN-γ] and interleukin 12 [IL-12]) from tumor non-parenchymal cells (NPCs) in 4T1 tumor bearing mice as compared to Cl66 tumor bearing mice and non-tumor bearing mice. Studies to assess where the MDSCs were expanding revealed that in 4T1 tumor bearing mice, frequency of the proliferating MDSCs is increased only in the spleen and liver compared to the non-tumor-bearing mice. Our studies also examined the affect of tumor burden on the trafficking of MDSCs. We observed that, after adoptive transfer of MDSCs isolated from 4T1 tumor-bearing mice, they arrest initially within the lungs in non-tumor-bearing mice. While in 4T1 tumor-bearing mice they rapidly transverse the lungs with arrest within the tumor tissue. We and others reported that the increase in MDSCs frequencies is associated with a decrease in CD3+ cells function and numbers. We observed a decrease in frequency of all T-cell subsets in the thymus of tumor bearing mice tested compared to the non-tumor-bearing mice suggesting defects in T-cell maturation associated with tumor burden. We investigated the effect of tumor burden on the phenotype of the CD3+ cells using the Annexin V staining and found that 4T1 tumor bearing mice have increased frequency of Annexin V positive CD3+ T-cells that are infiltrating tumor tissue compared to those in other organs. Citation Information: Clin Cancer Res 2010;16(14 Suppl):B52.

Study of Myeloid-Derived Suppressor Cell Accumulation in Lung of Tumor-Bearing Mice

The Expression of Myeloid-Derived Suppressor Cells in an Orthotopic Transplantation Liver Tumor Model in Mice

Different Characteristics of Myeloid-Derived Suppressor Cells from Septic and Tumor Bearing Mice

Identification of the Subpopulations of Myeloid-Derived Suppressor Cells and the Function Study in Elderly Tumor-Bearing Mice

Changes of MDSC, Treg and traditional T cells in lung tumor mice

Association of Myeloid-Derived Suppressor Cells (mdscs) in Peripheral Blood with Characteristics in Breast Cancer Patients.

Increased Circulating GrMyeloid-derived Suppressor Cells Correlated with Tumor Burden and Survival in Locally Advanced Cervical Cancer Patient

Tumor- and organ-dependent infiltration by myeloid-derived suppressor cells

[Expression and Significance of Myeloid-Derived Suppressor Cells-Associated Chemokine MIP-1γ and Its Receptor CCR1 in the Spleen of Hepatoma H22-bearing Mice].

Comparison of flow cytometry with different antibodies for enrichment of myeloid-derived suppressor cells from bone marrow of mouse models of orthotopic liver tumor

Interleukin 33 in Tumor Microenvironment is Crucial for the Accumulation and Function of Myeloid-Derived Suppressor Cells

Esablishment of Human Lung Cancer Model in the Scid Mouse

The change of proportion and inhibition on CD8~+T lymphocytes of myeloid-derived suppressor cells in peripheral blood from patients with non-small cell lung cancer

Myeloid-derived suppressor cells promote age-related increase of lung cancer growth via B7-H1.

Gr1+ myeloid-derived suppressor cells participate in the regulation of lung-gut axis during mouse emphysema model

A Novel Subset of B7-H3+CD14+HLA-DR−/lowmyeloid-derived Suppressor Cells Are Associated with Progression of Human NSCLC

[The Number of Myeloid-Derived Suppressor Cells in the Peripheral Blood and Tumor Tissues in Patients with Gastric Cancer and Its Clinical Significance].

Tumour-activated Liver Stromal Cells Regulate Myeloid-Derived Suppressor Cells Accumulation in the Liver

Study on characteristics and immune mechanisms of CD11b+GR-1+ myeloid-derived suppressor cells in elderly mice

Abstract B52: Characterizing the MDSCs phenotypes, expansion, and trafficking pattern and associated tumor-induced immune dysfunction

Targeting myeloid-derived suppressor cells by inhibiting hypoxia-inducible factor 1α could improve tumor progression